Body J-J, Bergmann P, Boonen S, Boutsen Y, Devogelaer J-P, Goemaere S, Kaufman J-M, Rozenberg S, Reginster J-Y
Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Osteoporos Int. 2010 Oct;21(10):1657-80. doi: 10.1007/s00198-010-1223-4. Epub 2010 May 18.
Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the currently available efficacy data on all new chemical entities which were granted a marketing authorization. Osteoporosis is widely recognized as a major public health concern. The availability of new therapeutic agents makes clinical decision-making in osteoporosis more complex. Nation-specific guidelines are needed to take into consideration the specificities of each and every health care environment. The present manuscript is the result of a National Consensus, based on a systematic review and a critical appraisal of the currently available literature. It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect.
有几种药物可用于治疗绝经后骨质疏松症。在日常临床实践中，这可能会使临床医生感到困惑。本手稿提供了基于证据的既往治疗指南更新内容，并对所有已获上市许可的新化学实体的现有疗效数据进行了批判性评估。骨质疏松症被广泛认为是一个重大的公共卫生问题。新治疗药物的出现使骨质疏松症的临床决策更加复杂。需要制定针对特定国家的指南，以考虑每个医疗环境的特殊性。本手稿是一项全国共识的成果，基于对现有文献的系统综述和批判性评价。它提供了基于证据的既往治疗指南更新内容，旨在为临床医生提供对骨质疏松症治疗效果的客观评估。
